Float Short %

10.9

Margin Of Safety %

Put/Call OI Ratio

0.42

EPS Next Q Diff

-0.19

EPS Last/This Y

1.33

EPS This/Next Y

1.21

Price

13.79

Target Price

32.67

Analyst Recom

1.42

Performance Q

13.13

Relative Volume

2.12

Beta

1.05

Ticker: RGNX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	RGNX	14.18	0.71	0.74	4858
2025-12-29	RGNX	14.31	0.72	0.35	4878
2025-12-30	RGNX	14.1	0.72	0.07	4889
2025-12-31	RGNX	14.41	0.74	0.00	4987
2026-01-02	RGNX	13.57	0.74	1.50	5001
2026-01-05	RGNX	13.39	0.78	0.13	5223
2026-01-06	RGNX	14.17	0.75	0.00	5367
2026-01-07	RGNX	15.25	0.74	0.02	5390
2026-01-08	RGNX	15.03	0.73	0.48	5441
2026-01-09	RGNX	14.56	0.73	0.20	5575
2026-01-12	RGNX	15.07	0.72	0.71	5655
2026-01-13	RGNX	15.06	0.72	0.03	5889
2026-01-14	RGNX	14.95	0.69	0.11	6013
2026-01-15	RGNX	13.75	0.70	0.37	6033
2026-01-16	RGNX	13.64	0.70	0.17	7673
2026-01-20	RGNX	14.13	0.39	0.50	4523
2026-01-21	RGNX	15	0.41	0.19	5121
2026-01-22	RGNX	15.96	0.43	0.46	5284
2026-01-23	RGNX	13.79	0.42	3.26	5794
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	RGNX	14.18	21.0	239.6	-3.26
2025-12-29	RGNX	14.27	21.0	243.4	-3.26
2025-12-30	RGNX	14.10	21.0	240.2	-3.26
2025-12-31	RGNX	14.40	21.0	245.5	-3.26
2026-01-02	RGNX	13.57	21.0	233.8	-3.26
2026-01-05	RGNX	13.40	21.0	240.3	-3.26
2026-01-06	RGNX	14.16	21.0	250.8	-3.26
2026-01-07	RGNX	15.24	21.0	253.2	-3.26
2026-01-08	RGNX	14.98	21.0	239.8	-3.26
2026-01-09	RGNX	14.57	22.6	238.2	-3.26
2026-01-12	RGNX	15.10	22.6	247.3	-3.26
2026-01-13	RGNX	15.03	22.6	241.8	-3.26
2026-01-14	RGNX	14.94	22.6	241.2	-3.26
2026-01-15	RGNX	13.76	22.6	230.8	-3.26
2026-01-16	RGNX	13.64	22.6	241.0	-3.26
2026-01-20	RGNX	14.11	22.6	247.7	-3.26
2026-01-21	RGNX	15.00	22.6	251.4	-3.26
2026-01-22	RGNX	15.98	22.6	251.5	-3.26
2026-01-23	RGNX	13.79	22.6	222.9	-3.26
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	RGNX	-0.80	-1.21	11.07
2025-12-29	RGNX	-0.80	-1.21	11.07
2025-12-30	RGNX	-0.80	-1.21	11.07
2025-12-31	RGNX	-0.80	-1.21	11.07
2026-01-02	RGNX	-0.80	-1.21	11.07
2026-01-05	RGNX	-0.80	-1.21	11.07
2026-01-06	RGNX	-0.80	-1.21	11.07
2026-01-07	RGNX	-0.80	-1.21	11.07
2026-01-08	RGNX	-0.80	-1.21	11.07
2026-01-09	RGNX	-0.80	-1.21	11.07
2026-01-12	RGNX	-0.78	-1.14	11.21
2026-01-13	RGNX	-0.71	-1.14	10.90
2026-01-14	RGNX	-0.71	-1.14	10.90
2026-01-15	RGNX	-0.71	-1.14	10.90
2026-01-16	RGNX	-0.71	-1.14	10.90
2026-01-20	RGNX	-0.71	-0.65	10.90
2026-01-21	RGNX	-0.71	-0.65	10.90
2026-01-22	RGNX	-0.71	-0.65	10.90
2026-01-23	RGNX	-0.71	-0.65	10.90
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.2

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-1.39

Insider Transactions

-0.71

Institutional Transactions

-0.65

Beta

1.05

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

72.1

Max Drawdown 5-Year %

-89.1

Target Price

32.67

P/E

Forward P/E

PEG

P/S

4.33

P/B

4.32

P/Free Cash Flow

EPS

-3.49

Average EPS Est. Cur. Y

-3.26

EPS Next Y. (Est.)

-2.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-110.29

Relative Volume

2.12

Return on Equity vs Sector %

-137.5

Return on Equity vs Industry %

-121.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.06

EBIT Estimation

222.9

REGENXBIO Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 353

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today

news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance

stock history RGNX – REGENXBIO Inc. invest stock market

stock prices RGNX premarket after hours

ticker RGNX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RGNX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y